Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCAT 2023 | An update on treatment of SCD

Lewis Hsu, MD, PhD, University of Illinois Chicago, Chicago, IL, discusses the exciting progress in sickle cell disease (SCD) treatment, generating enthusiastic anticipation within the community. The development of several cutting-edge gene therapies holds the potential for curative treatment and an improvement in quality of life of patients. They will come under FDA approval review before the end of 2023. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.